Retraction: The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK

Abstract

Silke Walleser Autiero, Natalie Hallas, Christopher D. Betts, Jeremy L. Ockrim. The above article from BJU International, published online on 25 June 2015 in Wiley Online Library (http://wileyonlinelibrary.com) has been retracted, at the authors' request, by agreement between the authors, the Journal Editor-in-Chief Prokar Dasgupta and John Wiley & Sons Inc. on behalf of BJU International. The retraction has been agreed following errors identified during an in-depth review of the model and the analyses. Whilst the authors are confident that the model inputs (literature, unit cost sources and clinical expert advice) were valid at the time of the analysis, there are integral errors in the structure of the model, which result in treatment costs and utility values being applied incorrectly to the patient population in both treatment arms. Consequently, the costs and QALYs calculated for both Sacral Neuromodulation and Botox are erroneous which affects the overall outcomes and conclusions of the publication. The principal source of the errors has been found to be the original model initially developed for Spain (Arlandis et al. Value Health. 2011 Mar-Apr;14(2):219-28), which was adapted for the UK for this analysis. The nature and complexity of the original model structure will not allow for any correction or revision; therefore, these errors are intractable. In view of this, the above article is being retracted. Reference 1 Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int 2015; 116: 945-54.